Share：
Share this content in WeChat
X
[Chinese] [PDF] 61 2
• Review •
Advances in structural and functional MRI studies of deep nuclei in Parkinson's disease patients
ZHU Minghui  HAO Lu 

DOI:10.12015/issn.1674-8034.2026.07.019.


[Abstract] Parkinson's disease is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and abnormal aggregation of α-synuclein. Deep brain nuclei, such as the subthalamic nucleus, globus pallidus, and substantia nigra, play critical roles in motor control, and their structural and functional abnormalities are key contributors to the symptoms of Parkinson's disease. In recent years, the rapid advancement of MRI techniques, especially high-field MRI, diffusion tensor imaging, and resting-state functional MRI, has provided powerful tools for in vivo, non-invasive investigation of the microstructure, white matter connectivity, and functional network activity of deep brain nuclei in Parkinson's disease patients. This review summarizes recent progress in structural and functional MRI studies of deep brain nuclei in Parkinson's disease, focusing on findings related to volume, morphology, iron deposition, white matter integrity, and abnormalities in local brain activity and network connectivity. It also discusses the correlations between these imaging alterations and disease stages, clinical symptoms (such as bradykinesia, tremor, and gait disturbances), and non-motor symptoms of Parkinson's disease. The review also analyzes current technical limitations in MRI studies of deep brain nuclei and, in light of emerging trends in neuroimaging, identifies future research directions, thereby providing imaging-based theoretical foundations and research references for exploring the pathogenesis of Parkinson's disease, enabling precise diagnosis and treatment, and guiding targeted interventions.
[Keywords] Parkinson's disease；deep nuclei；magnetic resonance imaging；structural magnetic resonance imaging；functional magnetic resonance imaging

ZHU Minghui   HAO Lu*  

Medical Imaging Center, the Second Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China

Corresponding author: HAO L, E-mail: 362314557@qq.com

Conflicts of interest   None.

Received  2026-01-18
Accepted  2026-06-05
DOI: 10.12015/issn.1674-8034.2026.07.019
DOI:10.12015/issn.1674-8034.2026.07.019.

[1]
ZHANG W B, WANG Y J, LING Y, et al. Disease burden of Parkinson's disease in China from 1990 to 2021 and its prediction[J]. Chinese Journal of Disease Control& Prevention, 2025, 29(1): 74-81. DOI: 10.16462/j.cnki.zhjbkz.2025.01.012.
[2]
WANG Z H, XIA H, WANG X B, et al. Trends and projection of the disease burden of Parkinson's disease in China[J]. Chinese Journal of Disease Control & Prevention, 2025, 29(6): 636-640, 661. DOI: 10.16462/j.cnki.zhjbkz.2025.06.003.
[3]
CHEN Z J, MA J, TANG N, et al. Analysis and prediction of trends in the disease burden of Parkinson's disease in China[J]. Chinese Journal of Prevention and Control of Chronic Diseases, 2022, 30(9): 649-654. DOI: 10.16386/j.cjpccd.issn.1004-6194.2022.09.003.
[4]
DIRKX J, GRILL F, DIJK N, et al. Depression in Parkinson's disease is associated with lower dopamine transporter binding in the caudate nucleus[J/OL]. Neurosci Appl, 2026, 5(S1): 105942 [2026-01-18]. https://doi.org/10.1016/J.NSA.2025.105942. DOI: 10.1016/J.NSA.2025.105942.
[5]
JIANG Y, QI Z, ZHU H, et al. Role of the globus pallidus in motor and non-motor symptoms of Parkinson's disease[J]. Neural Regen Res, 2025, 20(6): 1628-1643. DOI: 10.4103/NRR.NRR-D-23-01660.
[6]
WANDERS M, JANSEN J, WOLTERS A, et al. Altered white matter connection from the locus coeruleus to the thalamus in Parkinson's disease[J/OL]. Neuroimage, 2025, 5(4): 100292 [2026-01-18]. https://doi.org/10.1016/J.YNIRP.2025.100292. DOI: 10.1016/J.YNIRP.2025.100292.
[7]
BÉCHET S, LEONARD M, ADEMOLA E, et al. Precision prevention for neurodegenerative diseases: lessons learnt from Alzheimer's disease translated into perspectives for Parkinson's disease[J]. J Neural Transm, 2025, 133(2): 1-13. DOI: 10.1007/S00702-025-03090-Z.
[8]
CARASOL P L, HORTA M S, BARBA H A, et al. Disrupted visual-to-semantic dynamics promote visual hallucinations in Parkinson's disease[J/OL]. npj Parkinsons Dis, 2025, 12(1): 24 [2026-01-18]. https://doi.org/10.1038/S41531-025-01235-1. DOI: 10.1038/S41531-025-01235-1.
[9]
HE X Q, LI X Y, SHANG D D, et al. Application of radiomics based on 3D-T1WI and T2 FLAIR in the diagnosis of Parki nson's disease[J]. Chinese Journal of Medicine, 2024, 59(12): 1320-1325. DOI: 10.3969/j.issn.1008-1070.2024.12.009.
[10]
SISODIA V, WIGGERTS Y, BOOGAARD A A, et al. Nucleus Basalis of Meynert Volume and Cognitive Impairment in Parkinson's Disease Before and After Deep Brain Stimul of the Subthalamic Nucleus[J/OL]. Brain Sci, 2025, 15(6): 630 [2026-01-18]. https://doi.org/10.3390/brainsci15060630. DOI: 10.3390/brainsci15060630.
[11]
PETER A, PETERSEN M, WROBEL P, et al. Regional gray matter volumes are not predictive of axial symptom response to subthalamic Deep Brain Stimul in Parkinsonian patients[J/OL]. Parkinsonism Relat Disord, 2025, 130: 107193 [2026-01-18]. https://doi.org/10.1016/J.PARKRELDIS.2024.107193. DOI: 10.1016/J.PARKRELDIS.2024.107193.
[12]
MIKI Y, FOTI S C, ASI Y T, et al. Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study[J]. Brain, 2019, 142(9): 2813-2827. DOI: 10.1093/brain/awz189.
[13]
PICILLO M, TEPEDINO M F, ABATE F, et al. Midbrain MRI assessments in progressive supranuclear palsy subtypes[J]. J Neurol Neurosurg Psychiatry, 2020, 91(1): 98-103. DOI: 10.1136/jnnp-2019-321354.
[14]
WU T Y, LI C, JIAO Y, et al. Diagnostic and differential diagnostic value of conventional magnetic resonance morphometry in progressive supranuclear palsy[J]. Chinese Journal of Geriatrics, 2023, 42(2): 188-195. DOI: 10.3760/cma.j.issn.0254-9026.2023.02.009.
[15]
CONSTANTINIDES V C, GIAGKOU N, BRINIA M E, et al. In search of the optimal MRI marker for progressive supranuclear palsy: a large, single-center, retrospective study on the effect of phenotype, diagnostic certainty and disease duration[J/OL]. J Neurol, 2025, 272(8): 523 [2026-01-18]. https://doi.org/10.1007/s00415-025-12921-0. DOI: 10.1007/s00415-025-12921-0.
[16]
LIANG X, WANG Y, ANDRIKOPOULOS N, et al. Dysfunctional digestive tract highlights the metabolic hallmarks of nanoplastic-exacerbated Parkinson's pathology[J/OL]. npj Parkinsons Dis, 2025, 11(1): 300 [2026-01-18]. https://doi.org/10.1038/S41531-025-01145-2. DOI: 10.1038/S41531-025-01145-2.
[17]
TIAN C, ZHANG X D, WANG X Q, et al. Research progress on the application of voxel-based morphometry in gray matter changes related to Parkinson's disease[J]. Stereotactic and Functional Neurosurgery, 2024, 37(1): 54-62. DOI: 10.19854/j.cnki.1008-2425.2024.01.00011.
[18]
MENG L L, WANG X J, LI S T, et al. Application of diffusion tensor imaging in cognitive impairment of early Parkinson's disease[J]. Journal of Brain and Nervous Diseases, 2025, 33(5): 296-301. DOI: 10.19845/j.cnki.zfysjjbzz.2025.0120.
[19]
SU X C, LIAO X, CAI L J, et al. Diagnostic efficacy of diffusion tensor imaging combined with amide proton transfer-weighted imaging in early Parkinson's disease among elderly patients[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2026, 28(3): 372-376. DOI: 10.3969/j.issn.1009-0126.2026.03.021.
[20]
ZANG R L, WANG H, PAN W, et al. A preliminary study on brain microstructure changes of substantia nigra and insula in Parkinson's disease patients with freezing of gait based on DTI technique[J]. Chin J Magn Reson Imaging, 2025, 16(8): 13-18. DOI: 10.12015/issn.1674-8034.2025.08.003.
[21]
ZHANG Y Z, XU L L, ZHOU J, et al. Role of MR diffusion tensor imaging of midbrain and basal ganglia nuclei in the diagnosis of Parkinson's disease[J]. Journal of Molecular Imaging, 2021, 44(2): 327-331. DOI: 10.12122/j.issn.1674-4500.2021.02.27.
[22]
MENG P, LI Y X, ZHOU X Y, et al. Early diagnostic application of functional magnetic resonance imaging in Parkinson's disease with mild cognitive impairment[J]. Journal of China Clinic Medical Imaging, 2025, 36(12): 842-845, 854. DOI: 10.12117/jccmi.2025.12.002.
[23]
TOCZYLOWSKA B, MICHAŁOWSKA M, CHALIMONIUK M, et al. Diffusion tensor imaging technique for studying brain microstructural changes in Parkinson's disease patients[J]. Biocybern Biomed Eng, 2025, 45(3): 426-437. DOI: 10.1016/j.bbe.2025.03.006.
[24]
HARTMANN K, BIELAWSKI J, STEIN P K, et al. No significant correlation of subthalamic nuclei diffusion measures and disease burden: Evidence from 130 Parkinson's Disease Cases[J]. Deep Brain Stimul, 2025, 10: 1-12. DOI: 10.1016/J.JDBS.2025.06.002.
[25]
JENSEN J H, HELPERN J A, RAMANI A, et al. Diffusional kurtosis imaging: the quantification of non-gaussian water diffusion by means of magnetic resonance imaging[J]. Magn Reson Med, 2005, 53(6): 1432-1440. DOI: 10.1002/mrm.20508.
[26]
MODI A, MARIA S, KUCEROVA R J, et al. Brain Alterations Linked to the MPTP Mouse Model of Parkinson's Disease Uncovered by Diffusion Kurtosis Imaging and Magnetic Resonance Spectroscopy[J/OL]. CNS Neurosci Ther, 2026, 32(4): e70846[2026-01-18]. https://onlinelibrary.wiley.com/doi/abs/10.1002/cns.70846. DOI: 10.1002/CNS.70846.
[27]
ZHU N, HE S, HUANG Z, et al. Cerebral microstructural alteration patterns in motor subtypes of Parkinson's disease: a neurite orientation dispersion and density imaging study[J]. Quant Imaging Med Surg, 2025, 15(12): 12454-12466. DOI: 10.21037/QIMS-2025-34.
[28]
RONG Y, XU Z, ZHU Y, et al. Combination of quantitative susceptibility mapping and diffusion kurtosis imaging provides potential biomarkers for early-stage Parkinson's disease[J]. ACS Chem Neurosci, 2022, 13(18): 2699-2708. DOI: 10.1021/acschemneuro.2c00321.
[29]
WANG J, BI Q, GONG W, et al. Histogram analysis of diffusion kurtosis imaging of deep brain nuclei in Parkinson's disease with different motor subtypes[J/OL]. Clin Radiol, 2023, 78(12): e966-e974 [2026-01-18]. https://www.sciencedirect.com/science/article/abs/pii/S0009926023004221. DOI: 10.1016/J.CRAD.2023.09.008.
[30]
WELTON T, HARTONO S, TAN S, et al. A combined imaging based biomarker for Parkinson's disease using diffusion kurtosis and quantitative susceptibility mapping: 883[J/OL]. Mov Disord, 2021, 36: S387[2026-01-18]. https://doi.org/10.3389/fnagi.2024.1516479. DOI: 10.3389/fnagi.2024.1516479.
[31]
AMIT K, JANA R, ANAS A, et al. Diffusion kurtosis imaging detects the time-dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease[J]. J Neurochem, 2021, 158(3): 779-797. DOI: 10.1111/JNC.15449.
[32]
SHEN S M, LIU D G, YI Z Q, et al. Research progress of neurite orientation dispersion and density imaging in the central nervous system. Journal of Medical Imaging, 2025, 35(4): 121-124. DOI: 10.20258/j.cnki.1006-9011.2025.04.030.
[33]
ZHANG C, YUAN Y, SANG T, et al. Local white matter abnormalities in Parkinson's disease with mild cognitive impairment: Assessed with neurite orientation dispersion and density imaging[J]. J Neurosci Res, 2023, 101(7): 1154-1169. DOI: 10.1002/jnr.25181.
[34]
KOJI K, TAKU H, AYAMI O, et al. Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease[J]. Eur Radiol, 2016, 26(8): 2567-2577. DOI: 10.1007/s00330-015-4066-8.
[35]
JIANG S, ABLIZ A, SHAO H, et al. Characteristics and correlation study of cerebral iron deposition and microstructural changes in patients with early, middle, and advanced Parkinson's disease[J]. J Clin Radiol, 2024, 43(6): 912-916. DOI: 10.13437/j.cnki.jcr.2024.06.003.
[36]
MADELUNG F C, LØKKEGAARD A, FUGLSANG A S, et al. High-resolution mapping of substantia nigra in Parkinson's disease using 7 tesla magnetic resonance imaging[J/OL]. npj Parkinsons Dis, 2025, 11(1): 113 [2026-01-18]. https://doi.org/10.1038/S41531-025-00972-7. DOI: 10.1038/S41531-025-00972-7.
[37]
ZENG W, CAI J, ZHANG L, et al. Iron Deposition in Parkinson's Disease: A Mini-Review[J/OL]. Cell Mol Neurobiol, 2024, 44(1): 26 [2026-01-18]. https://doi.org/10.1007/S10571-024-01459-4. DOI: 10.1007/S10571-024-01459-4.
[38]
ONO D, KONDRAKUNTA S, MAK E, et al. Neuropathologic basis of quantitative susceptibility mapping in the substantia nigra: contributions of tau, pigmented neurons, and iron[J/OL]. Acta Neuropathol, 2026, 151(1): 17 [2026-01-18]. https://doi.org/10.1007/s00401-026-03002-x. DOI: 10.1007/s00401-026-03002-x.
[39]
YANG C, ZHOU L, TAO J, et al. Increased iron deposition in substantia nigra and red nucleus as a potential imaging biomarker for motor progression in idiopathic Parkinson's disease: Based on susceptibility-weighted imaging[J]. Journal of Molecular Imaging, 2025, 48(5): 569-573. DOI: 10.12122/j.issn.1674-4500.2025.05.20.
[40]
YANG T, ZHOU B, LI D J, et al. Meta-analysis of substantia nigra susceptibility-weighted imaging in the diagnosis of Parkinson's disease[J]. Chinese Journal of Medical Imaging Technology, 2015, 31(4): 508-511. DOI: 10.13929/j.1003-3289.2015.04.009.
[41]
SHI X F, HE N Y, ZHANG Y M, et al. Comparative study of tSWI and QSM in evaluating the swallow tail sign of substantia nigra in Parkinson's disease[J]. Radiol Pract, 2025, 40(8): 949-955. DOI: 10.13609/j.cnki.1000-0313.2025.08.001.
[42]
DIBASH B, RAMAKRISHNAN M, ANTHONY L, et al. Automated segmentation of substantia nigra and red nucleus using quantitative susceptibility mapping images: Application to Parkinson's disease[J/OL]. Comput Electr Eng, 2021, 91: 107091 [2026-01-18]. https://www.sciencedirect.com/science/article/abs/pii/S0045790621001002. DOI: 10.1016/J.COMPELECENG.2021.107091.
[43]
VRIES D E, HAGBOHM C, OUELLETTE R, et al. Clinical 7 Tesla magnetic resonance imaging: Impact and patient value in neurological disorders[J]. J Intern Med, 2025, 297(3): 244-261. DOI: 10.1111/JOIM.20059.
[44]
QING C, JINJIN H, DONGPING T, et al. Application value of multiparametric MRI for evaluating iron deposition in the substantia nigra in Parkinson's disease[J]. Front Neurol, 2023, 13: 1096966 [2026-01-18]. https://doi.org/10.3389/FNEUR.2022.1096966. DOI: 10.3389/FNEUR.2022.1096966.
[45]
GUO W, ZHANG D, SUN J, et al. Quantitative susceptibility mapping of subcortical iron deposition in Parkinson disease and multiple system atrophy: clinical correlations and diagnostic implications[J]. Quant Imaging Med Surg, 2024, 14(7): 4464-4474. DOI: 10.21037/QIMS-24-168.
[46]
ZANG S, PAN Y, CHEN M, et al. Different iron distribution patterns in Parkinson's disease and its motor subtypes: a quantitative susceptibility mapping study[J/OL]. Acta Radiol, 2024, 66(1): 2841851241297207 [2026-01-18]. https://doi.org/10.1177/02841851241297207. DOI: 10.1177/02841851241297207.
[47]
XINHUI W, WEI W, YAN B, et al. Intrinsic Brain Activity Alterations in Patients With Parkinson's disease[J]. Neurosci Lett, 2023, 809: 137298 [2026-01-18]. https://doi.org/10.1016/J.NEULET.2023.1. DOI: 10.1016/J.NEULET.2023.1.
[48]
WANG L, XIONG X, LIU J, et al. Gray matter structural and functional brain abnormalities in Parkinson's disease: a meta-analysis of VBM and ALFF data[J/OL]. J Neurol, 2025, 272(4): 276 [2026-01-18]. https://doi.org/10.1007/S00415-025-12934-3. DOI: 10.1007/S00415-025-12934-3.
[49]
LIU S, ZHU X, PU H, et al. Regional homogeneity differences in resting-state fMRI between Parkinson's disease and multiple system atrophy-parkinsonian type[J]. J Neural Transm, 2025, 133(1): 1-10. DOI: 10.1007/S00702-025-02940-0.
[50]
BAUDREXEL S, WITTE T, SEIFRIED C, et al. Resting state fMRI reveals increased subthalamic nucleus–motor cortex connectivity in Parkinson's disease[J]. NeuroImage, 2011, 55(4): 1728-1738. DOI: 10.1016/j.neuroimage.2011.01.017.
[51]
CHRISTIAN M, JULIAN C, ROBERT L, et al. Functional Connectivity Differences of the Subthalamic Nucleus Related to Parkinson's Disease[J]. Hum Brain Mapp, 2016, 37(3): 1235-1253. DOI: 10.1002/hbm.23099.
[52]
QIN B, TANG Y, QIN H, et al. Abnormal subthalamic nucleus functional connectivity and machine learning classification in Parkinson's disease: a multisite functional magnetic resonance imaging study[J/OL]. Front Aging Neurosci, 2025, 17: 1695806 [2026-01-18]. https://doi.org/10.3389/FNAGI.2025.1695806. DOI: 10.3389/FNAGI.2025.1695806.
[53]
ZHAO G H, CAO L X, ZHAO G H. Research progress on magnetic resonance imaging of impulsive-compulsive behaviors in Parkinson's disease[J]. Chinese J Neurol, 2022, 55(5): 544-550. DOI: 10.3760/cma.j.cn113694-20211009-00687.
[54]
CHU C, LIU S, HE N, et al. Subthalamic stimulation modulates motor network in Parkinson's disease: recover, relieve and remodel[J]. Brain, 2023, 146(7): 2780-2791. DOI: 10.1093/brain/awad011.
[55]
WÓJCIK R, DĘBSKA A, ZACZKOWSKI K, et al. Deep Brain Stimul for Parkinson's disease—a narrative review[J/OL]. Biomedicines, 2025, 13(10): 2430 [2026-01-18]. https://doi.org/10.3390/biomedicines13102430. DOI: 10.3390/biomedicines13102430.
[56]
MIDDLEBROOKS H E, BOT M, PATRIAT R, et al. Multi-institutional recommendations on the use of 7 T MRI in deep brain stimulation[J]. J. Neurosurg., 2025, 143(5):1165-1178. DOI: 10.3171/2025.2.JNS242247.
[57]
DUNDON M N, RIZOR J E, STASIAK E J, et al. Incentive valence differentially engages open- and closed-loop basal ganglia circuits during movement initiation[J/OL]. Proc Natl Acad Sci U S A, 2026, 123(19): e2537314123[2026-01-18]. https://doi.org/10.1073/PNAS.2537314123. DOI: 10.1073/PNAS.2537314123.
[58]
JINGYA M, MOHAMED T, VICTORIA K, et al. Use of Functional MRI in Deep Brain Stimul in Parkinson's Diseases: A Systematic Review[J/OL]. Front Neurol, 2022, 13: 849918 [2026-01-18]. https://doi.org/10.3389/FNEUR.2022.849918. DOI: 10.3389/FNEUR.2022.849918.
[59]
WANG Q, XIA J G, TIAN W Z. Research progress on resting-state brain network functional magnetic resonance imaging in Parkinson's disease with cognitive impairment[J]. Chin J Magn Reson Imaging, 2020, 11(11): 1044-1047. DOI: 10.12015/issn.1674-8034.2020.11.018.
[60]
EISENSTEIN T, GROENEWALD K, VAN HILLEGONDSBERG L, et al. Cholinergic degeneration in prodromal and early Parkinson's: a link to present and future disease states[J/OL]. Brain, 2025 [2026-01-18]. https://doi.org/10.1002/mds.29635. DOI: 10.1002/mds.29635.
[61]
KHAN Z A, SHAFIQ M A, SINGH J, et al. Application of Functional MRI in Parkinson's Disease and Default Mode Network: Review of the Literature[J]. Can J Neurol Sci, 2025: 1-8. DOI: 10.1017/cjn.2025.110.
[62]
MIJALKOV M, VOLPE G, PEREIRA J B. Directed brain connectivity identifies widespread functional network abnormalities in Parkinson's disease[J]. Cereb Cortex, 2022, 32(3): 593-607. DOI: 10.1093/cercor/bhab244.
[63]
GARCIA R P G, MIDDLEBROOKS E, MEI S, et al. Functional and Structural Connectivity Correlates of Axial Symptom Outcomes After Pallidal Deep Brain Stimul in Parkinson's Disease[J/OL]. Brain Sci, 2025, 15(11): 1245 [2026-01-18]. https://doi.org/10.3390/BRAINSCI15111245. DOI: 10.3390/BRAINSCI15111245.
[64]
ZHANG C, WU C, ZHANG H, et al. Disrupted resting-state functional connectivity of the nucleus basalis of meynert in Parkinson's disease with mild cognitive impairment[J]. Neuroscience, 2020, 442: 228-236. DOI: 10.1016/j.neuroscience.2020.06.025.
[65]
SLATER M N, MELZER R T, MYALL J D, et al. Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic Resonance Imaging Evidence[J]. Mov Disord, 2024, 39(12): 2155-2172. DOI: 10.1002/MDS.30023.
[66]
LI C M, WANG R, ZHOU J Y, et al. Value of amide proton transfer magnetic resonance imaging in the diagnosis of Parkinson's disease. Functional and Molecular Medical Imaging (Electronic Edition), 2014, 3(3): 428-431. DOI: 10.3969/j.issn.2095-2252.2014.03.016.
[67]
LI X Y, TIAN Y T, SU W, et al. Quantitative metrics of chemical exchange saturation transfer imaging in substantia nigra and red nucleus in Parkinson's disease[J]. Chin J Radiol, 2024, 58(6): 603-610. DOI: 10.3760/cma.j.cn112149-20230803-00065.
[68]
TIAN Y, LI X, CHEN H, et al. Altered Nigral Amide Proton Transfer Imaging Signal Concordant With Motor Asymmetry in Parkinson's Disease: A Multipool CEST MRI Study[J/OL]. NMR Biomed, 2025, 38(2): e5310[2026-01-18]. https://onlinelibrary.wiley.com/doi/10.1002/nbm.5310. DOI: 10.1002/NBM.5310.
[69]
YUAN F Z, TAN C L, HE Z, et al. 3D multi-voxel ¹H-MRS study of substantia nigra in midbrain in Parkinson's disease[J]. J Med Imaging, 2016, 26(11): 1949-1953. DOI: 10.20258/j.cnki.1006-9011.2016.11.001.
[70]
GU W, HE C, CHEN J, et al. Proton magnetic resonance spectroscopy for the early diagnosis of Parkinson disease in the substantia nigra and globus pallidus: a meta-analysis with trial sequential analysis[J/OL]. Front Neurol, 2022, 13: 838230 [2026-01-18]. https://doi.org/10.3389/fneur.2022.838230. DOI: 10.3389/fneur.2022.838230.
[71]
HUANG M, YU H, LYU X, et al. Region-specific cerebral metabolic alterations in Parkinson's disease patients with/without mild cognitive impairment[J]. Neuroscience, 2024, 551: 254-261. DOI: 10.1016/J.NEUROSCIENCE.2024.05.039.
[72]
GÖRANSSON N, TAPPER S, LUNDBERG P, et al. Thalamic metabolite changes after subthalamic nucleus Deep Brain Stimul in Parkinson's disease: an exploratory magnetic resonance spectroscopy study[J/OL]. Front Neurol, 2025, 16: 1662142 [2026-01-18]. https://doi.org/10.3389/fneur.2025.1662142. DOI: 10.3389/fneur.2025.1662142.
[73]
KUMARI S, KUMARAN S, RAJAN R, et al. Neurobiochemical alterations in patients with idiopathic Parkinson's disease in sensorimotor cortex using 1H-MRS[J]. Neuroscience, 2025, 5881-5810. DOI: 10.1016/J.NEUROSCIENCE.2025.10.014.
[74]
YU Q, ZHANG Y, HUANG P, et al. Midbrain Energy Homeostasis Biomarker for Differential Diagnosis of Early-Stage Parkinson Disease: A 1H and 31P MRI Study[J/OL]. Radiology, 2026, 319(1): e251533[2026-01-18]. https://doi.org/10.1148/RADIOL.251533. DOI: 10.1148/RADIOL.251533.
[75]
ACCIOLY M R A, MENEZES O V, CALIXTO H L, et al. Machine Learning-Based Diagnostic Prediction Model Using T1-Weighted Striatal Magnetic Resonance Imaging for Early-Stage Parkinson's Disease Detection[J]. Acad Radiol, 2025, 32(7): 4177-4187. DOI: 10.1016/J.ACRA.2025.04.001.
[76]
ZHANG N G, WANG X, LI L L, et al. (2024). Radiomics assessment of Parkinson's disease using diffusion kurtosis imaging[J]. Chinese Journal of Medical Imaging Technology, 2024, 40(9): 1323-1326. DOI: 10.13929/j.issn.1003-3289.2024.09.010.
[77]
CHEN H, BAI F Y, AN P, et al. Value of texture analysis based on neuromelanin imaging in the diagnosis of Parkinson's disease[J]. Chin J Magn Reson Imaging, 2025, 16(6), 34-41, 47. DOI: 10.12015/issn.1674-8034.2025.06.007.
[78]
SHUTING B, HUIZE P, XIAOLU L, et al. Multi-parametric radiomics of conventional T1 weighted and susceptibility-weighted imaging for differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy[J/OL]. BMC Med Imaging, 2023, 23(1): 204 [2026-01-18]. https://doi.org/10.1186/s12880-023-01166-4. DOI: 10.1186/s12880-023-01166-4.
[79]
KIM J, LEE H, PARK S, et al. Integrated analysis of multimodal brain imaging and clinical data for Parkinson's disease subtyping using deep learning[J/OL]. Med Image Anal, 2024, 94: 103245 [2026-01-18]. https://doi.org/10.1016/j.media.2024.103245. DOI: 10.1016/j.media.2024.103245.
[80]
SEIFY N, KHEZERLOO D, JAHANSHAHI R A, et al. Longitudinal assessment of MRI-based radiomics feature changes in caudate and putamen over progression of parkinson's disease[J/OL]. Egypt J Radiol Nucl Med, 2025, 56(1): 135 [2026-01-18]. https://doi.org/10.1186/S43055-025-01552-8. DOI: 10.1186/S43055-025-01552-8.
[81]
FUSHIMI Y, GHASSABAN K, SETHI S K, et al. Integrated evaluation of Nigrosome 1 sign, neuromelanin-sensitive MR and iron deposition[J]. Jpn J Radiol, 2026, 44: 24-34. DOI: 10.1007/s11604-025-01858-7.
[82]
KANG J J, CHEN Y, XU G D, et al. Combining quantitative susceptibility mapping to radiomics in diagnosing Parkinson's disease and assessing cognitive impairment[J]. Eur Radiol, 2022, 32(10): 6992-7003. DOI: 10.1007/s00330-022-08790-8.
[83]
XIE G Q, WU K H, BI Q, et al. Research progress of multimodal MRI and radiomics in Parkinson's disease with depression[J]. Chin J Magn Reson Imaging, 2022, 13(6): 135-138. DOI: 10.12015/issn.1674-8034.2022.06.027.
[84]
HOSSEINI S M, AGHAMIRI R M S, PANAHI M. Cross-regional radiomics: a novel framework for relationship-based feature extraction with validation in Parkinson's disease motor subtyping[J/OL]. BioData Min, 2025, 18(1): 67 [2026-01-18]. https://doi.org/10.1186/s13040-025-00458-5. DOI: 10.1186/s13040-025-00458-5.
[85]
ZHANG X, LI H, XIA X, et al. Predicting Parkinson's disease and its progression based on radiomics in T1-weight images and α-synuclein in cerebrospinal fluid[J/OL]. npj Parkinsons Dis, 2025, 11(1): 273 [2026-01-18]. https://doi.org/10.1038/s41531-025-01079-9. DOI: 10.1038/s41531-025-01079-9.
[86]
MADELUNG C F, LØKKEGAARD A, FUGLSANG S A, et al. High-resolution mapping of substantia nigra in Parkinson's disease using 7 tesla magnetic resonance imaging[J/OL]. npj Parkinsons Dis, 2025, 11(1): 113 [2026-01-18]. https://doi.org/1038/s41531-025-00972-7. DOI: 10.1038/s41531-025-00972-7.

PREV Research progress on negative functional connectivity between the default mode network and dorsal attention network in subjective cognitive decline
NEXT Research progress on MRI of the comorbidity between depression and gastrointestinal abnormalities
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn